Loading...
XNYS
BSX
Market cap144bUSD
Dec 05, Last price  
97.52USD
1D
-0.20%
1Q
-9.05%
Jan 2017
350.86%
Name

Boston Scientific Corp

Chart & Performance

D1W1MN
XNYS:BSX chart
P/E
77.98
P/S
8.63
EPS
1.25
Div Yield, %
Shrs. gr., 5y
1.05%
Rev. gr., 5y
9.30%
Revenues
16.75b
+17.61%
6,283,000,0007,821,000,0008,357,000,0008,050,000,0008,188,000,0007,806,000,0007,622,000,0007,249,000,0007,143,000,0007,380,000,0007,477,000,0008,386,000,0009,048,000,0009,823,000,00010,735,000,0009,913,000,00011,888,000,00012,682,000,00014,240,000,00016,747,000,000
Net income
1.85b
+16.38%
628,000,000-3,577,000,000-495,000,000-2,072,000,000-1,025,000,000-1,065,000,000441,000,000-4,068,000,000-121,000,000267,000,000-239,000,000347,000,000104,000,0001,671,000,0004,700,000,000-140,000,0001,041,000,000698,000,0001,593,000,0001,854,000,000
CFO
3.44b
+37.24%
903,000,0001,845,000,000934,000,0001,216,000,000835,000,000325,000,0001,008,000,0001,260,000,0001,082,000,0001,269,000,000600,000,000972,000,0001,426,000,000310,000,0001,836,000,0001,508,000,0001,870,000,0001,526,000,0002,503,000,0003,435,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
IPO date
May 19, 1992
Employees
45,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT